Abstract
Greater than the sum of its parts: Artemisinins are currently in phase I-II clinical trials against breast, colorectal and non-small-cell lung cancers. In an attempt to offer increased specificity, a series of hybrid artemisinin-polypyrrole minor groove binder conjugates are described. DNA binding/modelling studies and preliminary biological evaluation give insights into their mechanism of action and the potential of this strategy.
| Original language | English |
|---|---|
| Pages (from-to) | 709-718 |
| Number of pages | 10 |
| Journal | ChemMedChem |
| Volume | 8 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 May 2013 |
Keywords
- Artemisinin
- Binding studies
- Cytotoxicity
- DNA
- Molecular modelling